A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
NCT01152398
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
BIOLOGICAL:
MVA-BN-HER2
Sponsor
Bavarian Nordic